The BRAF Knockout Ca Ski Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population in which the BRAF gene has been disrupted within the human Ca Ski cervical carcinoma cell line, eliminating expression of the encoded serine/threonine kinase. This heterogenous loss-of-function model provides an advantageous alternative to clonal isolates by capturing population-level responses while minimizing clonal artifacts. Researchers can interrogate BRAF-dependent signaling and the functional consequences of MAPK pathway inhibition without the confounding influence of a single genetic background, making it particularly suitable for studies requiring robust average phenotypes across a genetically diverse pool of edited cells.
The host Ca Ski line is an epithelial human cervical carcinoma model originally derived from a mesenteric metastasis. It faithfully retains malignant characteristics of the primary tumor, including anchorage-independent growth and invasive potential, and is widely employed to dissect oncogenic signaling, therapeutic responses, and disease progression mechanisms. Its well-characterized nature and compatibility with diverse molecular and functional readouts render it an ideal platform for creating targeted gene knockouts to examine pathway dependencies in a cervical cancer context.
BRAF encodes a cytoplasmic serine/threonine kinase that functions as a central transducer of the RAS-RAF-MEK-ERK cascade. Upon activation by GTP-bound RAS isoforms (HRAS, KRAS, NRAS) and receptor tyrosine kinases such as EGFR, BRAF homodimerizes or heterodimerizes with CRAF (RAF1), phosphorylates MEK1 (MAP2K1) and MEK2 (MAP2K2), which in turn activate the effector kinases ERK1 (MAPK3) and ERK2 (MAPK1). Phosphorylated ERK translocates to the nucleus and regulates transcription factors including ELK1, FOS, JUN, and MYC, thereby promoting expression of Cyclin D1 (CCND1) and other genes that drive cell cycle progression and survival. BRAF activity is modulated by scaffold proteins (KSR), chaperones (HSP90), and 14-3-3 adaptors, and cross-talks with the PI3K/AKT pathway. In these knockout polyclonal cells, disruption of BRAF ablates signal relay from RAS to MEK/ERK, causing loss of downstream transcriptional output and MAPK-dependent phenotypes.
Although activating BRAF mutations are uncommon in cervical cancer, the MAPK/ERK axis is frequently hyperactivated through upstream oncogenic inputs, including growth factor receptor overexpression or HPV oncoprotein signaling. The BRAF knockout Ca Ski polyclonal cells therefore offer a refined tool to deconvolute BRAF-dependent versus BRAF-independent pathway contributions. Experiments using this model can delineate the reliance of cervical carcinoma proliferation, survival, migration, and invasion on BRAF-mediated signaling, and can uncover compensatory activation of CRAF or PI3K/AKT pathways. Consequently, the knockout cells enable identification of synthetic lethal interactions and assessment of RAF/MEK inhibitor specificity in a cervical carcinoma setting.
Typical applications include elucidating BRAF function in cervical cancer via western blotting for phospho-ERK, RT-qPCR of downstream targets (FOS, MYC, CCND1), and phospho-ERK ELISA; measuring cell proliferation and colony formation; evaluating drug resistance to RAF or MEK inhibitors; identifying synthetic lethal partners through RNAi or CRISPR screens; and investigating tumor?Cstroma crosstalk using co-culture or invasion assays. Transcriptomic profiling (RNA-seq) and apoptosis assays further expand the utility of this model. For additional technical information or custom inquiries, please contact Ascent Research.
